Jodie Pope Morrison

Insider · CEO · QTTB

Jodie Pope Morrison files insider transactions with the SEC as a ceo of Q32 Bio (QTTB). We hold 2 disclosed purchases and sales filed since 24 September 2014, 1 of them in the last 90 days.

Files forQTTB
Disclosed buys and sells2 in all, 1 in the last 90 days
Last disclosure27 August 2026

Positions held

7 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 25 March 2024 — 25 August 2026CEO · Q32 Bio (QTTB)18 Form 4 lines · source: SEC Form 4
Filed 26 June 2024 — 25 July 2025Director · Verve Therapeutics (VERV)4 Form 4 lines · source: SEC Form 4
Filed 25 July 2017 — 15 June 2022Director · Aileron Therapeutics (ALRN)6 Form 4 lines · source: SEC Form 4
Filed 12 December 2018 — 6 June 2019Director · Akebia Therapeutics (AKBA)7 Form 4 lines · source: SEC Form 4
Filed 21 June 2016 — 12 December 2018Interim CEO · Keryx Biopharmaceuticals (KERX)8 Form 4 lines · source: SEC Form 4
Filed 30 June 2017 — 30 June 2017Director · Novus Therapeutics (NVUS)1 Form 4 line · source: SEC Form 4
Filed 22 September 2014 — 8 January 2016President and CEO · Tokai Pharmaceuticals (TKAI)27 Form 4 lines · source: SEC Form 4

Everything they disclosed

71 entries, newest first — one per disclosure report, one per Form 4 line

▼ sold on the open market 9,845 shares of Q32 BioSEC Form 427 August 2026Common Stock · traded 25 August 2026 · filed 27 August 2026
was granted 132,000 shares of Q32 BioSEC Form 420 July 2026Common Stock · traded 16 July 2026 · filed 20 July 2026
was granted 132,000 shares of Q32 BioSEC Form 420 March 2026Common Stock · traded 24 February 2026 · filed 20 March 2026
was granted 132,000 shares of Q32 BioSEC Form 420 March 2026Common Stock · traded 24 February 2026 · filed 20 March 2026
▼ sold on the open market 9,896 shares of Q32 BioSEC Form 427 February 2026Common Stock · traded 25 February 2026 · filed 27 February 2026
▼ sold on the open market 9,896 shares of Q32 BioSEC Form 427 February 2026Common Stock · traded 25 February 2026 · filed 27 February 2026
▼ sold on the open market 22,506 shares of Q32 BioSEC Form 44 December 2025Common Stock · traded 2 December 2025 · filed 4 December 2025
▼ sold on the open market 10,494 shares of Q32 BioSEC Form 428 August 2025Common Stock · traded 26 August 2025 · filed 28 August 2025
returned to the issuer 267,541 shares of Verve Therapeutics (a derivative holding)SEC Form 428 July 2025Stock Option (right to buy) · traded 25 July 2025 · filed 28 July 2025
returned to the issuer 42,200 shares of Verve Therapeutics (a derivative holding)SEC Form 428 July 2025Stock Option (right to buy) · traded 25 July 2025 · filed 28 July 2025
was granted 42,200 shares of Verve Therapeutics (a derivative holding)SEC Form 46 June 2025Stock Option (right to buy) · traded 5 June 2025 · filed 6 June 2025
returned to the issuer 152,700 shares of Q32 Bio (a derivative holding)SEC Form 426 February 2025Stock Option (Right to Buy) · traded 24 February 2025 · filed 26 February 2025
was granted 152,700 shares of Q32 Bio (a derivative holding)SEC Form 426 February 2025Stock Option (Right to Buy) · traded 24 February 2025 · filed 26 February 2025
returned to the issuer 152,700 shares of Q32 Bio (a derivative holding)SEC Form 426 February 2025Stock Option (Right to Buy) · traded 24 February 2025 · filed 26 February 2025
was granted 152,700 shares of Q32 Bio (a derivative holding)SEC Form 426 February 2025Stock Option (Right to Buy) · traded 24 February 2025 · filed 26 February 2025
returned to the issuer 16,901 shares of Q32 Bio (a derivative holding)SEC Form 426 February 2025Stock Option (Right to Buy) · traded 24 February 2025 · filed 26 February 2025
was granted 16,901 shares of Q32 Bio (a derivative holding)SEC Form 426 February 2025Stock Option (Right to Buy) · traded 24 February 2025 · filed 26 February 2025
returned to the issuer 394,445 shares of Q32 Bio (a derivative holding)SEC Form 426 February 2025Stock Option (Right to Buy) · traded 24 February 2025 · filed 26 February 2025
was granted 394,445 shares of Q32 Bio (a derivative holding)SEC Form 426 February 2025Stock Option (Right to Buy) · traded 24 February 2025 · filed 26 February 2025
was granted 132,000 shares of Q32 BioSEC Form 426 February 2025Common Stock · traded 24 February 2025 · filed 26 February 2025
was granted 267,541 shares of Verve Therapeutics (a derivative holding)SEC Form 428 June 2024Stock Option (right to buy) · traded 26 June 2024 · filed 28 June 2024
was granted 394,445 shares of Q32 Bio (a derivative holding)SEC Form 427 March 2024Stock Option (Right to Buy) · traded 25 March 2024 · filed 27 March 2024
was granted 54,500 shares of Aileron Therapeutics (a derivative holding)SEC Form 417 June 2022Stock Option (right to buy) · traded 15 June 2022 · filed 17 June 2022
was granted 96,000 shares of Aileron Therapeutics (a derivative holding)SEC Form 417 June 2021Stock Option (right to buy) · traded 15 June 2021 · filed 17 June 2021
was granted 12,500 shares of Aileron Therapeutics (a derivative holding)SEC Form 418 June 2020Stock Option (right to buy) · traded 17 June 2020 · filed 18 June 2020
was granted 25,000 shares of Aileron Therapeutics (a derivative holding)SEC Form 421 June 2019Stock Option (right to buy) · traded 19 June 2019 · filed 21 June 2019
was granted 20,100 shares of Akebia Therapeutics (a derivative holding)SEC Form 410 June 2019Stock Option (Right to buy) · traded 6 June 2019 · filed 10 June 2019
was granted 13,700 shares of Akebia TherapeuticsSEC Form 410 June 2019Common Stock · traded 6 June 2019 · filed 10 June 2019
returned to the issuer 110,000 shares of Keryx Biopharmaceuticals (a derivative holding)SEC Form 413 December 2018Stock Option · traded 12 December 2018 · filed 13 December 2018
returned to the issuer 120,000 shares of Keryx BiopharmaceuticalsSEC Form 413 December 2018Common Stock · traded 12 December 2018 · filed 13 December 2018
was granted 44,919 shares of Akebia TherapeuticsSEC Form 413 December 2018Common Stock · traded 12 December 2018 · filed 13 December 2018
was granted 18,716 shares of Akebia Therapeutics (a derivative holding)SEC Form 413 December 2018Stock Option (Right to buy) · traded 12 December 2018 · filed 13 December 2018
was granted 11,229 shares of Akebia Therapeutics (a derivative holding)SEC Form 413 December 2018Stock Option (Right to buy) · traded 12 December 2018 · filed 13 December 2018
was granted 11,229 shares of Akebia Therapeutics (a derivative holding)SEC Form 413 December 2018Stock Option (Right to buy) · traded 12 December 2018 · filed 13 December 2018
was granted 25,000 shares of Akebia Therapeutics (a derivative holding)SEC Form 413 December 2018Stock Option (Right to buy) · traded 12 December 2018 · filed 13 December 2018
was granted 30,000 shares of Keryx Biopharmaceuticals (a derivative holding)SEC Form 412 July 2018Stock Options (right to buy) · traded 30 June 2018 · filed 12 July 2018
was granted 10,000 shares of Keryx BiopharmaceuticalsSEC Form 412 July 2018Common Stock · traded 30 June 2018 · filed 12 July 2018
was granted 10,000 shares of Aileron Therapeutics (a derivative holding)SEC Form 425 June 2018Stock Option (right to buy) · traded 21 June 2018 · filed 25 June 2018
was granted 100,000 shares of Keryx BiopharmaceuticalsSEC Form 414 May 2018Common Stock · traded 10 May 2018 · filed 14 May 2018
was granted 20,000 shares of Aileron Therapeutics (a derivative holding)SEC Form 427 July 2017Stock Option (right to buy) · traded 25 July 2017 · filed 27 July 2017
was granted 18,000 shares of Novus Therapeutics (a derivative holding)SEC Form 45 July 2017Stock Option (Right to Buy) · traded 30 June 2017 · filed 5 July 2017
was granted 10,000 shares of Keryx BiopharmaceuticalsSEC Form 420 June 2017Common Stock · traded 9 June 2017 · filed 20 June 2017
was granted 30,000 shares of Keryx Biopharmaceuticals (a derivative holding)SEC Form 420 June 2017Stock Options (right to buy) · traded 9 June 2017 · filed 20 June 2017
was granted 50,000 shares of Keryx Biopharmaceuticals (a derivative holding)SEC Form 423 June 2016Stock Options (right to buy) · traded 21 June 2016 · filed 23 June 2016
exercised options over 8,015 shares of Tokai PharmaceuticalsSEC Form 48 January 2016Common Stock · traded 8 January 2016 · filed 8 January 2016
exercised options over 20,000 shares of Tokai PharmaceuticalsSEC Form 48 January 2016Common Stock · traded 8 January 2016 · filed 8 January 2016
exercised options over 8,015 shares of Tokai Pharmaceuticals (a derivative holding)SEC Form 48 January 2016Stock Option (right to buy) · traded 8 January 2016 · filed 8 January 2016
exercised options over 20,000 shares of Tokai Pharmaceuticals (a derivative holding)SEC Form 48 January 2016Stock Option (right to buy) · traded 8 January 2016 · filed 8 January 2016
was granted 189,000 shares of Tokai Pharmaceuticals (a derivative holding)SEC Form 417 December 2015Stock Option (right to buy) · traded 15 December 2015 · filed 17 December 2015
exercised options over 12,000 shares of Tokai PharmaceuticalsSEC Form 430 July 2015Common Stock · traded 28 July 2015 · filed 30 July 2015
▼ sold on the open market 12,000 shares of Tokai PharmaceuticalsSEC Form 430 July 2015Common Stock · traded 28 July 2015 · filed 30 July 2015
exercised options over 564 shares of Tokai PharmaceuticalsSEC Form 430 July 2015Common Stock · traded 29 July 2015 · filed 30 July 2015
▼ sold on the open market 564 shares of Tokai PharmaceuticalsSEC Form 430 July 2015Common Stock · traded 29 July 2015 · filed 30 July 2015
exercised options over 7,000 shares of Tokai PharmaceuticalsSEC Form 430 July 2015Common Stock · traded 29 July 2015 · filed 30 July 2015
exercised options over 3,000 shares of Tokai PharmaceuticalsSEC Form 430 July 2015Common Stock · traded 29 July 2015 · filed 30 July 2015
exercised options over 12,000 shares of Tokai Pharmaceuticals (a derivative holding)SEC Form 430 July 2015Stock Option (right to buy) · traded 28 July 2015 · filed 30 July 2015
exercised options over 564 shares of Tokai Pharmaceuticals (a derivative holding)SEC Form 430 July 2015Stock Option (right to buy) · traded 29 July 2015 · filed 30 July 2015
exercised options over 7,000 shares of Tokai Pharmaceuticals (a derivative holding)SEC Form 430 July 2015Stock Option (right to buy) · traded 29 July 2015 · filed 30 July 2015
exercised options over 3,000 shares of Tokai Pharmaceuticals (a derivative holding)SEC Form 430 July 2015Stock Option (right to buy) · traded 29 July 2015 · filed 30 July 2015
exercised options over 2,574 shares of Tokai PharmaceuticalsSEC Form 424 July 2015Common Stock · traded 22 July 2015 · filed 24 July 2015
exercised options over 7,426 shares of Tokai PharmaceuticalsSEC Form 424 July 2015Common Stock · traded 22 July 2015 · filed 24 July 2015
exercised options over 2,574 shares of Tokai Pharmaceuticals (a derivative holding)SEC Form 424 July 2015Stock Option (right to buy) · traded 22 July 2015 · filed 24 July 2015
exercised options over 7,426 shares of Tokai Pharmaceuticals (a derivative holding)SEC Form 424 July 2015Stock Option (right to buy) · traded 22 July 2015 · filed 24 July 2015
exercised options over 8,000 shares of Tokai PharmaceuticalsSEC Form 430 June 2015Common Stock · traded 26 June 2015 · filed 30 June 2015
▼ sold on the open market 8,000 shares of Tokai PharmaceuticalsSEC Form 430 June 2015Common Stock · traded 26 June 2015 · filed 30 June 2015
exercised options over 8,000 shares of Tokai PharmaceuticalsSEC Form 430 June 2015Common Stock · traded 29 June 2015 · filed 30 June 2015
▼ sold on the open market 8,000 shares of Tokai PharmaceuticalsSEC Form 430 June 2015Common Stock · traded 29 June 2015 · filed 30 June 2015
exercised options over 8,000 shares of Tokai Pharmaceuticals (a derivative holding)SEC Form 430 June 2015Stock Option (right to buy) · traded 26 June 2015 · filed 30 June 2015
exercised options over 8,000 shares of Tokai Pharmaceuticals (a derivative holding)SEC Form 430 June 2015Stock Option (right to buy) · traded 29 June 2015 · filed 30 June 2015
was granted 134,134 shares of Tokai Pharmaceuticals (a derivative holding)SEC Form 417 October 2014Stock Option (right to buy) · traded 15 October 2014 · filed 17 October 2014
was granted 165,251 shares of Tokai Pharmaceuticals (a derivative holding)SEC Form 424 September 2014Stock Option (right to buy) · traded 22 September 2014 · filed 24 September 2014

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.